Dabigatran 150 mg or 110 mg	Placebo or dabigatran 50 mg	Cardiovascular and all-cause mortality rates	26936	27107	Cardiovascular and all-cause mortality rates were lowest in the 110 mg twice daily and 150 mg twice daily groups compared with the lower dose dabigatran and placebo groups
Dabigatran	Enoxaparin or placebo	Rates of myocardial infarction 	1664	1756	Dabigatran had similar myocardial infarction rates when compared with enoxaparin or placebo.
Dabigatran	Warfarin	Rates of myocardial infarction 	18087	18324	The rates of MI in RE-LY measured 0.82%, 0.81%, and 0.64% per year for the dabigatran 110 mg twice daily, dabigatran 150 mg twice daily, and warfarin treatment groups, respectively; the differences did not reach statistical significance.
Dabigatran 150 mg BID	Warfarin	Risk of vascular death	21237	21409	The risk of vascular death for dabigatran 150 mg twice daily was significantly lower than for well-controlled warfarin (hazard ratio [HR] 0.85, 95% CI 0.72â€“0.99, P = 0.04).
